LON:ABC Abcam - ABC Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Abcam plc Please log in to your account or sign up in order to add this asset to your watchlist. GBX 1,226 +123.00 (+11.15%) (As of 12/13/2022) Add Compare Share Share Today's Range 1,115▼ 1,25950-Day Range 1,226▼ 1,22652-Week Range 1,013.57▼ 1,760Volume6.37 million shsAverage Volume392,791 shsMarket Capitalization£2.81 billionP/E Ratio20,433.33Dividend Yield0.91%Price TargetGBX 1,700 ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlinesOptions Chain About Abcam (LON:ABC) StockAbcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.Read More Receive ABC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter. Email Address ABC Stock News HeadlinesMarch 20, 2023 | marketwatch.comTetracosactide Market Share and Forecast till 2028March 20, 2023 | marketwatch.comTissue Microarray Market Outlook and Forecast till 2029March 21, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 20, 2023 | ft.comCambridge university’s economic impact worth £30bn a year, analysis showsMarch 20, 2023 | marketwatch.comEpigenetics Market Size and Forecast till 2028March 20, 2023 | baystreet.caABCAM out with ResultsMarch 20, 2023 | marketwatch.comKjeldahl Market Top Players and Forecast till 2028March 20, 2023 | ft.comCambridge university’s economic impact is worth £30bn a yearMarch 21, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 20, 2023 | marketwatch.comChemical Probes Market Size and Forecast till 2029March 20, 2023 | marketwatch.comAlfacalcidol Market Outlook and Forecast till 2029March 17, 2023 | marketwatch.comOxidative Stress Assay Market Statistics and Industry Share Analysis Forecast 2023-2028March 17, 2023 | marketwatch.comGlobal G-quadruplex (G4) Antibody Market Size by Type (Polyclonal, Monoclonal) Forecast from 2023 to 2028March 16, 2023 | uk.finance.yahoo.comGlobal Affinity Ligands Market - Analysis By Type, End Use, By Region, By Country: Market Size, Insights, Competition, Covid-19 Impact and ForecastMarch 16, 2023 | finance.yahoo.comGlobal Apoptosis Market to Reach $6.6 Billion by 2030March 16, 2023 | finance.yahoo.comGlobal Epigenetics Market to Reach $3.5 Billion by 2030March 16, 2023 | marketwatch.comProtein A Purification Resin Market Growth and Forecast till 2028March 15, 2023 | marketwatch.comAlfacalcidol Market Trends and Opportunities: A Deep Dive Analysis 2023-2028March 15, 2023 | marketwatch.comMultiplex Assay Technology Market Size 2023 Research Report by Emerging Trends Analysis and Forecast till 2027March 15, 2023 | marketwatch.comExploring Untapped Opportunities in the Osteocalcin ELISA Kit Market from 2023 to 2030March 15, 2023 | marketwatch.comSingleplex Immunoassay Market 2023, Top Factors that Will Boost the Singleplex Immunoassay MarketMarch 14, 2023 | marketwatch.comPurified Human Proteins Market to Set a Phenomenal Growth of Million Worldwide by 2023March 14, 2023 | marketwatch.comAmbroxol Hydrochloride Market Forecast 2023 To 2029 Size, Global Predictive AnalyticsMarch 13, 2023 | marketwatch.comAntigen ELISA Kit Market Size 2023 Research Report by Emerging Trends Analysis and Forecast till 2027March 12, 2023 | marketwatch.comGlobal Creatinine Assay Kits Market 2023 Outlook By Product, Application And End-Use | Trends and Forecast To 2030 By VMReportsMarch 10, 2023 | marketwatch.comAntibody and Protein Labeling Kits Market Application, Product, Sales and Forecast 2023-2028March 10, 2023 | marketwatch.comAerrane Market Size forecast till 2030: Growth Factor, Global Revenue, Competitive Strategies, and Production Cost.See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ABC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:ABC CUSIPN/A CIKN/A Webwww.abcam.com Phone+44-1223-696000FaxN/AEmployees1,650Year FoundedN/APrice Target and Rating Average Stock Price ForecastGBX 1,700 High Stock Price ForecastGBX 1,700 Low Stock Price ForecastGBX 1,700 Forecasted Upside/Downside+38.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio20,433.33 Forward P/E Ratio33.28 P/E Growth1.57Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio31.60 Current Ratio1.27 Quick Ratio0.89 Sales & Book Value Annual Sales£350.40 million Price / Sales8.02 Cash FlowGBX 50.93 per share Price / Cash Flow24.07 Book ValueGBX 318.30 per share Price / Book3.85Miscellaneous Outstanding Shares229,272,000Free FloatN/AMarket Cap£2.81 billion OptionableOptionable BetaN/A Key ExecutivesMr. Alan Thomas Hirzel BS (Age 54)M.B.A., M.S., MBA, MS, CEO & Exec. Director Comp: $1.23MMr. Michael Shaun Baldock B.A. (Age 58)CFO & Director Comp: $881.14kMr. Mark DermodyInterim CIOJames StaveleyVP of Investor RelationsMarc PerkinsGen. Counsel & Company Sec.Emma SceatsSr. VP of Sales, Service & Bus. Devel.Mr. Nick SkinnerSr. VP of HRMr. Mark BushfieldSr. VP of Research & InnovationMs. Kirstie Speck BBusScHead of Consumer InsightsMs. Yvonne ChienSr. VP of Customer ExperienceMore ExecutivesKey CompetitorsBTGLON:BTGGenusLON:GNSOxford Nanopore TechnologiesLON:ONTDechra PharmaceuticalsLON:DPHUDG HealthcareLON:UDGView All CompetitorsInsidersMichael BaldockSold 18,032 sharesTotal: £25.64 M ($1,422.00/share)Mara G AspinallBought 3,037 shares on 4/4/2022Total: £4.36 M ($1,436.00/share)View All Insider Transactions ABC Stock - Frequently Asked Questions Should I buy or sell Abcam stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abcam in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABC shares. View ABC analyst ratings or view top-rated stocks. What is Abcam's stock price forecast for 2023? 1 Wall Street research analysts have issued 12-month price targets for Abcam's shares. Their ABC share price forecasts range from GBX 1,700 to GBX 1,700. On average, they anticipate the company's share price to reach GBX 1,700 in the next twelve months. This suggests a possible upside of 38.7% from the stock's current price. View analysts price targets for ABC or view top-rated stocks among Wall Street analysts. How have ABC shares performed in 2023? Abcam's stock was trading at GBX 1,226 at the beginning of the year. Since then, ABC stock has increased by 0.0% and is now trading at GBX 1,226. View the best growth stocks for 2023 here. What other stocks do shareholders of Abcam own? Based on aggregate information from My MarketBeat watchlists, some companies that other Abcam investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), HSBC (HSBA), Royal Dutch Shell (RDSA) and Centrica (CNA). What is Abcam's stock symbol? Abcam trades on the London Stock Exchange (LON) under the ticker symbol "ABC." How do I buy shares of Abcam? Shares of ABC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Abcam's stock price today? One share of ABC stock can currently be purchased for approximately GBX 1,226. How much money does Abcam make? Abcam (LON:ABC) has a market capitalization of £2.81 billion and generates £350.40 million in revenue each year. How many employees does Abcam have? The company employs 1,650 workers across the globe. How can I contact Abcam? Abcam's mailing address is 330 Cambridge Science Park, CAMBRIDGE, CB4 0FL, United Kingdom. The official website for the company is www.abcam.com. The company can be reached via phone at +44-1223-696000. This page (LON:ABC) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.